par Joffroy, Alfred
Référence Revue médicale de Bruxelles, 19, 4, page (A393-A397)
Publication Publié, 1998-09
Article révisé par les pairs
Résumé : Sumatriptan and other selective serotonin agonists represent a major breakthrough in acute migraine treatment. These drugs are very efficacious and generally devoided of important side effects, but they are expensive and therefore have to be compared with other, more conventional drugs with established or assumed efficacy. We summarize the pharmacologic characteristics of Sumatriptan and give recommendations about its use in clinical practice.